BG108217A - Метод за инхибиране на адхезия - Google Patents

Метод за инхибиране на адхезия Download PDF

Info

Publication number: BG108217A
Authority: BG; Bulgaria
Prior art keywords: alkyl; het; cor; cycloalkyl; halogen
Prior art date: 2001-04-10

Application number

BG108217A

Other languages

Bulgarian (bg)

English (en)

Inventor

Robert Willette

Original Assignee

Smithkline Beecham Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-10

Filing date

2003-10-01

Publication date

2004-12-30

2003-10-01 Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation

2004-12-30 Publication of BG108217A publication Critical patent/BG108217A/bg

Links

230000015572 biosynthetic process Effects 0.000 title claims abstract description 15
230000002401 inhibitory effect Effects 0.000 title claims description 7
238000000034 method Methods 0.000 title description 18
125000000217 alkyl group Chemical group 0.000 claims description 48
229910052799 carbon Inorganic materials 0.000 claims description 15
150000001875 compounds Chemical class 0.000 claims description 15
229910052739 hydrogen Inorganic materials 0.000 claims description 14
-1 -OR 11 Chemical group 0.000 claims description 12
229910052736 halogen Inorganic materials 0.000 claims description 12
150000002367 halogens Chemical class 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
125000003342 alkenyl group Chemical group 0.000 claims description 4
125000000304 alkynyl group Chemical group 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
KSSPHFGIOASRDE-HNNXBMFYSA-N 2-[(4s)-8-[2-[6-(methylamino)pyridin-2-yl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-4,5-dihydro-1h-2-benzazepin-4-yl]acetic acid Chemical compound CNC1=CC=CC(CCOC=2C=C3CN(CC(F)(F)F)C(=O)[C@H](CC(O)=O)CC3=CC=2)=N1 KSSPHFGIOASRDE-HNNXBMFYSA-N 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000003282 alkyl amino group Chemical group 0.000 claims description 2
125000005021 aminoalkenyl group Chemical group 0.000 claims description 2
125000004103 aminoalkyl group Chemical group 0.000 claims description 2
125000005014 aminoalkynyl group Chemical group 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
125000000623 heterocyclic group Chemical group 0.000 claims description 2
229910052757 nitrogen Inorganic materials 0.000 claims description 2
125000005188 oxoalkyl group Chemical group 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
125000003831 tetrazolyl group Chemical group 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 2
RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 1
125000001475 halogen functional group Chemical group 0.000 claims 1
102100022337 Integrin alpha-V Human genes 0.000 abstract description 14
108010048673 Vitronectin Receptors Proteins 0.000 abstract description 14
239000002464 receptor antagonist Substances 0.000 abstract description 12
229940044551 receptor antagonist Drugs 0.000 abstract description 12
238000001356 surgical procedure Methods 0.000 description 18
241001465754 Metazoa Species 0.000 description 17
241000283973 Oryctolagus cuniculus Species 0.000 description 16
210000001035 gastrointestinal tract Anatomy 0.000 description 16
229940125904 compound 1 Drugs 0.000 description 10
238000011888 autopsy Methods 0.000 description 8
239000000203 mixture Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 6
239000007788 liquid Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
206010060932 Postoperative adhesion Diseases 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000969 carrier Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
102000019997 adhesion receptor Human genes 0.000 description 2
108010013985 adhesion receptor Proteins 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
238000000227 grinding Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
230000001599 osteoclastic effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
SNAKUPLQASYKTC-AWEZNQCLSA-N (3S)-3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC[C@@H]1CN(CCC1)C(=O)NC1=CC=CC=C1 SNAKUPLQASYKTC-AWEZNQCLSA-N 0.000 description 1
LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
LIDBMZYKSAXTQG-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-sulfamoylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(N)(=O)=O)C=CC=1 LIDBMZYKSAXTQG-UHFFFAOYSA-N 0.000 description 1
FJPUKTJEFOXMJX-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[1-(hydroxymethyl)cyclopropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2(CC2)CO)C=CC=1 FJPUKTJEFOXMJX-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
208000034827 Neointima Diseases 0.000 description 1
206010034238 Pelvic adhesions Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
KDSYNTPPPISIJB-UHFFFAOYSA-N [3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]phenyl]-(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Chemical compound NCc1cc(OCc2cccc(c2)C(=O)N2CC(O)C(F)C2)nc(c1)C(F)(F)F KDSYNTPPPISIJB-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
230000003436 cytoskeletal effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
229960004563 eprosartan Drugs 0.000 description 1
230000035558 fertility Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000002350 laparotomy Methods 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000000754 myometrium Anatomy 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
235000021400 peanut butter Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000005086 pumping Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
238000007790 scraping Methods 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)

BG108217A 2001-04-10 2003-10-01 Метод за инхибиране на адхезия BG108217A (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US28269301P	2001-04-10	2001-04-10

Publications (1)

Publication Number	Publication Date
BG108217A true BG108217A (bg)	2004-12-30

Family

ID=23082703

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108217A BG108217A (bg)	2001-04-10	2003-10-01	Метод за инхибиране на адхезия

Country Status (26)

Country	Link
EP (1)	EP1385504B1 (de)
JP (1)	JP4394882B2 (de)
KR (1)	KR20030087069A (de)
CN (1)	CN1248692C (de)
AP (1)	AP2003002894A0 (de)
AT (1)	ATE417612T1 (de)
AU (1)	AU2002305164B2 (de)
BG (1)	BG108217A (de)
BR (1)	BR0208789A (de)
CA (1)	CA2443734A1 (de)
CZ (1)	CZ20032767A3 (de)
DE (1)	DE60230404D1 (de)
EA (1)	EA006202B1 (de)
EC (1)	ECSP034799A (de)
ES (1)	ES2319877T3 (de)
HU (1)	HUP0303725A3 (de)
IL (1)	IL158272A0 (de)
MA (1)	MA26159A1 (de)
MX (1)	MXPA03009344A (de)
NO (1)	NO20034513L (de)
NZ (1)	NZ528577A (de)
OA (1)	OA12505A (de)
PL (1)	PL364526A1 (de)
UA (1)	UA75395C2 (de)
WO (1)	WO2002083125A1 (de)
ZA (1)	ZA200307621B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200635902A (en) *	2004-12-21	2006-10-16	Smithkline Beecham Corp	Methods and formulations
RU2744540C1 (ru) *	2020-02-18	2021-03-11	Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ профилактики спаечного процесса при операциях на брюшной полости в условиях паренхиматозного кровотечения в эксперименте

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA60311C2 (uk) *	1996-10-02	2003-10-15	Смітклайн Бічам Корпорейшн	Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

2002
- 2002-04-10 CN CNB028097874A patent/CN1248692C/zh not_active Expired - Fee Related
- 2002-04-10 HU HU0303725A patent/HUP0303725A3/hu unknown
- 2002-04-10 AP APAP/P/2003/002894A patent/AP2003002894A0/en unknown
- 2002-04-10 KR KR10-2003-7013214A patent/KR20030087069A/ko not_active Abandoned
- 2002-04-10 BR BR0208789-8A patent/BR0208789A/pt not_active IP Right Cessation
- 2002-04-10 IL IL15827202A patent/IL158272A0/xx unknown
- 2002-04-10 JP JP2002580929A patent/JP4394882B2/ja not_active Expired - Fee Related
- 2002-04-10 EA EA200301109A patent/EA006202B1/ru not_active IP Right Cessation
- 2002-04-10 WO PCT/US2002/011285 patent/WO2002083125A1/en not_active Ceased
- 2002-04-10 CA CA002443734A patent/CA2443734A1/en not_active Abandoned
- 2002-04-10 PL PL02364526A patent/PL364526A1/xx not_active Application Discontinuation
- 2002-04-10 ES ES02733968T patent/ES2319877T3/es not_active Expired - Lifetime
- 2002-04-10 NZ NZ528577A patent/NZ528577A/en unknown
- 2002-04-10 MX MXPA03009344A patent/MXPA03009344A/es active IP Right Grant
- 2002-04-10 CZ CZ20032767A patent/CZ20032767A3/cs unknown
- 2002-04-10 DE DE60230404T patent/DE60230404D1/de not_active Expired - Lifetime
- 2002-04-10 AT AT02733968T patent/ATE417612T1/de not_active IP Right Cessation
- 2002-04-10 AU AU2002305164A patent/AU2002305164B2/en not_active Ceased
- 2002-04-10 OA OA1200300271A patent/OA12505A/en unknown
- 2002-04-10 EP EP02733968A patent/EP1385504B1/de not_active Expired - Lifetime
- 2002-10-04 UA UA2003109182A patent/UA75395C2/uk unknown
2003
- 2003-09-30 ZA ZA200307621A patent/ZA200307621B/en unknown
- 2003-10-01 BG BG108217A patent/BG108217A/bg unknown
- 2003-10-06 MA MA27339A patent/MA26159A1/fr unknown
- 2003-10-08 NO NO20034513A patent/NO20034513L/no not_active Application Discontinuation
- 2003-10-09 EC EC2003004799A patent/ECSP034799A/es unknown

Also Published As

Publication number	Publication date
ECSP034799A (es)	2004-01-28
JP2004525959A (ja)	2004-08-26
EP1385504A4 (de)	2007-03-14
PL364526A1 (en)	2004-12-13
HUP0303725A3 (en)	2009-08-28
CZ20032767A3 (cs)	2004-12-15
OA12505A (en)	2006-05-29
NO20034513D0 (no)	2003-10-08
IL158272A0 (en)	2004-05-12
ZA200307621B (en)	2004-04-21
AU2002305164B2 (en)	2005-07-28
CA2443734A1 (en)	2002-10-24
AP2003002894A0 (en)	2003-12-31
CN1248692C (zh)	2006-04-05
ATE417612T1 (de)	2009-01-15
MXPA03009344A (es)	2004-02-12
DE60230404D1 (de)	2009-01-29
NO20034513L (no)	2003-12-04
UA75395C2 (en)	2006-04-17
NZ528577A (en)	2005-01-28
ES2319877T3 (es)	2009-05-14
EA200301109A1 (ru)	2004-02-26
KR20030087069A (ko)	2003-11-12
EA006202B1 (ru)	2005-10-27
WO2002083125A1 (en)	2002-10-24
EP1385504A1 (de)	2004-02-04
CN1509170A (zh)	2004-06-30
MA26159A1 (fr)	2004-07-01
HUP0303725A2 (hu)	2004-03-01
BR0208789A (pt)	2004-03-09
EP1385504B1 (de)	2008-12-17
JP4394882B2 (ja)	2010-01-06

Publication	Publication Date	Title
US20220152058A1 (en)	2022-05-19	Methods and compositions for treating various disorders
AU2009240662B2 (en)	2015-07-02	Biocompatible crosslinked hydrogels, drug-loaded hydrogels and methods of using the same
JPWO2003043655A1 (ja)	2005-03-10	頻尿の治療剤
JP2000507544A (ja)	2000-06-20	痛みの治療方法
BR112020003973A2 (pt)	2020-09-01	combinação de agentes ativos para o tratamento de doenças pulmonares intersticiais fibrosantes progressivas (pf-ild)
JP2003012557A (ja)	2003-01-15	不安及びうつ病のための多剤併用治療
US8075908B2 (en)	2011-12-13	Apparatus and method for reducing the occurrence of post-surgical adhesions
ZA200105275B (en)	2002-09-26	New use of melagatran.
Eggleston et al.	2001	Use of a hyaluronate membrane for jejunal anastomosis in horses
JP5244089B2 (ja)	2013-07-24	鎮痛剤およびビタミンを含む医薬組成物
JP4394882B2 (ja)	2010-01-06	接着形成阻害方法
CN117442703B (zh)	2024-06-25	Elamipretide在制备预防和/或治疗肌腱损伤的药物中的应用
JPS648603B2 (de)	1989-02-14
ES2359721T3 (es)	2011-05-26	Composición farmacéutica para el tratamiento de fracturas óseas.
CN1972931B (zh)	2010-05-26	用于治疗高血压症与血清高尿酸血症和/或高胆固醇血症合并发作的药物
AU2002305164A1 (en)	2003-04-17	Method of inhibiting adhesion formation
US20040142918A1 (en)	2004-07-22	Method of inhibiting adhesion formation
JPH089538B2 (ja)	1996-01-31	卒中治療用薬剤
JP2012136478A (ja)	2012-07-19	骨壊死予防及び／又は治療剤
JPS59157021A (ja)	1984-09-06	動脈硬化症予防治療剤
JP2002541099A (ja)	2002-12-03	免疫調節組成物およびその使用方法
HK40081935A (en)	2023-06-02	Treatment of amyotrophic lateral sclerosis
JPH01272523A (ja)	1989-10-31	グアニジノ安息香酸誘導体を有効成分として含有する抗動脈硬化剤
LT5474B (lt)	2008-02-25	2,5-dihidroksibenzensulfoninių junginių panaudojimas sutrikimų, paremtų no produkcijos susilpnėjimu, gydymui ir/arba edhf funkcijos reguliavimui
CZ2000292A3 (cs)	2000-10-11	Farmaceutický prostředek aktivní při snižování produkce proteinu MCP-1